Browse > Home / Archive: December 2008

HTG Collaborates with HC-LITT

HTG SIGNS COLLABORATION AGREEMENT WITH HARVARD CATALYST LABORATORY FOR INNOVATIVE TRANSLATIONAL TECHNOLOGIES AT HARVARD MEDICAL SCHOOL

Tucson, Ariz.—December 1, 2008—HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA™) system and service partner for the life sciences industry, today announced a collaboration agreement with researchers at Harvard Catalyst Laboratory for Innovative Translational Technologies (HC-LITT) at Harvard Medical School. Under the terms of the agreement, HTG and HC-LITT will collaborate to generate a novel microRNA biogenesis assay that can measure expression of both pre-microRNA (miRNA) precursors, mature-microRNAs and regulated RNA using HTG’s qNPA™ (quantitative Nuclease Protection Assay) technology.

Researchers at the HC-LITT are investigating the implications of differential microRNA expression in human diseases such as cancer. MicroRNAs are singlestranded functional RNA species encoded in the human genome that regulate protein expression of numerous gene products. HC-LITT will utilize HTG’s technology to evaluate regulation of miRNA biogenesis by established oncogenic cell signaling pathways in order to develop novel diagnostic markers and therapeutic targets for the molecular characterization and treatment of cancer.

“We selected HTG’s technology due to the high precision and sensitivity of the product platform,” said Winston Patrick Kuo, Director, Harvard Catalyst Laboratory for Innovative Translational Technologies at Harvard Medical School. “I’m looking forward to utilizing HTG’s gene expression assay technology and imagers for HC-LITT’s research initiatives.”

HTG’s qNPA technology is used to carry out quantitative, multiplexed gene-based drug discovery programs, including target validation, HTS lead optimization, metabolism, toxicology and clinical development. HTG’s platform is highly flexible and designed for high throughput automation; it allows scientists to test any sample, including fixed tissues, without RNA extraction or target amplification. The technology is ideal for detecting small yet important changes in gene expression levels which other gene expression platforms cannot reliably detect.

About Harvard Catalyst Laboratory for Innovative Translational Technologies
The Harvard Catalyst Laboratory for Innovative Translational Technologies (HC-LITT) is scaling existing infrastructure to support translational research by providing early access to enabling, leading-edge genomic and proteomic technologies. The goal of the HC-LITT is to facilitate innovative, technologic contributions to novel translational research. The development of unique methods is pivotal to identifying nascent methodologies to diagnose and treat human disease. The collaborative research model is designed to bring together a myriad of innovative technologies in one place and put them to use in the hands of inventors and thought leaders.

About HTG
Privately-held HTG is based in Tucson, Arizona. Investors in the company include Solstice Capital, Valley Ventures, Merck Capital Ventures, Village Ventures and Arcturus Capital. Additional information is available at www.htgenomics.com.

 

Fred Pollock Joins HTG

HTG NAMES FREDRICK POLLOCK VP OF CORPORATE DEVELOPMENT

Tucson, Ariz.—November 24, 2008— HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA™) system and service partner for the life sciences industry, today announced it has appointed Fredrick L. Pollock to Vice President of Corporate Development. Pollock will be responsible for leading commercial sales efforts in the academic and research markets, spearheading efforts for bio-marker and signature discovery collaborations and supporting commercialization efforts for the company’s mid-density array product line.

Over the past eight years, Pollack has served in management, sales and business development roles most recently as Director of Strategic Businesses and Translational Medicine at Affymetrix, Inc., a leading microarray technology vendor. His accomplishments include implementing a global alliance management program, developing strategies for sales expansions, launching several partner clinical laboratory improvement amendments (CLIA) certified clinical tests, and securing multi-millions in additional sales.

“Fred brings a wealth of industry knowledge and expertise to our leadership team and he will help us accelerate our commercial and corporate development efforts,” said TJ Johnson, President and CEO, HTG. “HTG’s portfolio strategy is to leverage the precision of the qNPA assay into the mid-plex market and establish the assay as a new standard for gene expression based diagnostics. Fred’s background is perfectly suited to help us in these specific areas.”

“I am eager to work with the HTG management team and build on the proven success of HTG’s platform to further expand the company’s customer base,” said Fred Pollock. “With my biotechnology and translational medical industry experience this was an ideal fit. I look forward to contributing to HTG’s future success in my new capacity.”

Prior to Affymetrix, Pollock worked at Amersham Pharmacia Biotech, now part of GE Healthcare, for 11 years. He most recently served as a business unit manager where he was responsible for managing sales in the central United States. He also held positions at The University of Texas Southwestern Medical Center and Photon Marketing.

Pollock earned a B.A. in Molecular Biology from the University of North Texas. HTG’s qNPA technology is used to carry out quantitative multiplexed, gene-based drug discovery programs, including target validation, HTS lead optimization, metabolism, toxicology and clinical development. HTG’s platform allows scientists to test any sample, including fixed tissues, while avoiding the need for extraction or target amplification. The platform provides high-quality quantitative test results enabling clients to compress drug discovery and development program timelines, increase program success and reduce costs.

About HTG
Privately-held HTG is based in Tucson, Arizona. Investors in the company include Solstice Capital, Valley Ventures, Merck Capital Ventures, Village Ventures and Arcturus Capital. Additional information is available at www.htgenomics.com.